RxDoctor Payments Data

Ricardo Bellera, MD

Interventional Cardiology · Humble, TXNPI 1285860080

Payments from drug & device makers

$17,071in general payments, 2019–2025

Across 498 payments — averaging $34.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Medtronic$2K
  • Abbott$2K
  • Edwards Lifesciences$2K
  • Novartis$1K
  • Abiomed$916
  • plus $5K from 35 others

What the payments were for

  • Travel & lodging$4,77028%
  • Food & beverage$12,17471%
  • Education$1271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,071 in reported general payments places this provider in the 60th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$345,167
Medicare patients
800
Services billed
1,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan110$127,031
EliquisApixaban86$82,020
XareltoRivaroxaban65$63,044
FarxigaDapagliflozin Propanediol63$46,437
OzempicSemaglutide45$43,488
Repatha SyringeEvolocumab23$20,907
BrilintaTicagrelor19$17,525
JardianceEmpagliflozin17$13,721
EdarbyclorAzilsartan Med/Chlorthalidone46$13,072
VerquvoVericiguat11$12,093
EdarbiAzilsartan Medoxomil20$11,797
Nifedipine ErNifedipine103$3,248
Amiodarone Hcl39$1,842
Carvedilol264$1,748
Torsemide117$1,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,257$127,031110 claims
PfizerEliquis$97$82,02086 claims
AstraZenecaFarxiga, Brilinta$400$63,96282 claims
Johnson & JohnsonXarelto$464$63,04465 claims
Novo NordiskOzempic$608$43,48845 claims
Boehringer IngelheimJardiance$107$13,72117 claims
MerckVerquvo$686$12,09311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Humble

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →